-+ 0.00%
-+ 0.00%
-+ 0.00%

CULLINAN THERAPEUTICS - TO INITIATE PHASE 1/2 STUDY OF CLN-049 COMBINATION IN UNTREATED AML

Reuters·07/28/2026 11:00:01

Please log in to view news